<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; interministerial</title>
	<atom:link href="http://www.tapanray.in/tag/interministerial/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Price Negotiation For Patented Drugs: Still Continues A Policy Paralysis</title>
		<link>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=price-negotiation-for-patented-drugs-continues-a-policy-paralysis</link>
		<comments>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/#comments</comments>
		<pubDate>Mon, 12 Dec 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[policy Paralysis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8006</guid>
		<description><![CDATA[Many poor and even middle-income patients, who spend their entire life savings for treatment of life-threatening ailments, such as, cancer, have been virtually priced out of the access to patented new drugs, across the world. As articulated by the American &#8230; <a href="http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Astronomical Prices of Patented Cancer Drugs: A Solution in Sight?</title>
		<link>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight</link>
		<comments>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/#comments</comments>
		<pubDate>Thu, 20 Feb 2014 13:25:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[astronomical]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmaco-economics]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reserachers]]></category>
		<category><![CDATA[sight]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5014</guid>
		<description><![CDATA[Astronomical prices of patented anti-cancer dugs have become a subject of great concern not just in India. It is becoming an issue across the world. After issuing the first ever Compulsory License (CL) for Nexavar of Bayer in India, the &#8230; <a href="http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/astronomical-prices-of-patented-cancer-drugs-a-solution-in-sight/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
